Connect Biopharma Holdings Ltd (CNTB) Stock Analysis
Verdict: WATCH (do not buy)
Positive Phase 2 COPD data offers upside, but $38.3M cash against a $51.6M annual burn makes dilution the dominant near-term risk.
Investment score: 41/100
Analysis as of
7-factor investment score
- Valuation: 35/100 (weight 20%)
- Financial Health: 20/100 (weight 15%)
- Technical Momentum: 40/100 (weight 15%)
- Earnings Quality: 35/100 (weight 15%)
- Insider Sentiment: 80/100 (weight 10%)
- Analyst Consensus: 75/100 (weight 10%)
- Risk-Adjusted Return: 30/100 (weight 15%)
Connect Biopharma Holdings Ltd opportunities and risks
What speaks for CNTB
- Rademikibart Phase 2 COPD Efficacy
What speaks against CNTB
- Imminent Financing Dilution Risk
Peers and competitors
| Ticker | P/E | P/S | EV/EBITDA | Gross margin | Net margin | FCF yield |
|---|---|---|---|---|---|---|
| CNTB | n/a | 23.6x | n/a | 100.0% | -1763.4% | -46.1% |
| FBIO | 0.7x | 1.0x | n/a | 62.5% | 163.3% | 177.0% |
| TENX | n/a | 0.0x | 1.0x | 0.0% | 0.0% | -91.8% |
| SPRO | 8.6x | 1.6x | 2.8x | 100.0% | 17.2% | 27.9% |
| RNXT | n/a | 35.6x | n/a | 84.4% | -621.7% | -17.0% |
| RNTX | n/a | 0.0x | n/a | 0.0% | 0.0% | -83.8% |
| Peer median | n/a | 1.0x | n/a | 62.5% | 0.0% | -17.0% |
Frequently asked questions about Connect Biopharma Holdings Ltd (CNTB)
Is CNTB stock a good investment?
The TradeMates model rates Connect Biopharma Holdings Ltd as WATCH (do not buy) with an investment score of 41/100. Positive Phase 2 COPD data offers upside, but $38.3M cash against a $51.6M annual burn makes dilution the dominant near-term risk. This is algorithmic model output, not personal investment advice.
Is CNTB stock a buy?
The TradeMates model verdict for CNTB is WATCH (do not buy) with an investment score of 41/100. Treat this as a model signal to review, not a personal buy recommendation.